Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
McKesson
Baxter
Mallinckrodt
Argus Health

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,897,623

« Back to Dashboard

Summary for Patent: 7,897,623
Title:.omega.-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Carlisle, MA), Khire; Uday R. (Orange, CT), Lowinger; Timothy B. (Carlisle, MA), Scott; William J. (Guilford, CT), Smith; Roger A. (Chester Springs, PA), Wood; Jill E. (Ft. Collins, CO), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert N. (North Haven, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Application Number:11/845,597
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,897,623
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,897,623
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,897,623

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Argus Health
Chubb
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.